Anemia Drugs News Monitoring

Global Autoimmune Hemolytic Anemia Treatment Market Growth: To Reach $1.99 Billion by 2029 with an Impressive 8.9% CAGR

The Business Research Company's Autoimmune Hemolytic Anemia Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, June 13, 2025 /⁨EINPresswire.com⁩/ -- What Does The Data On …

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

The FDA has granted fast-track designation to anti-IL1RAP antibody nadunolimab (CAN04) as a frontline treatment in combination with gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) with high levels of …

Key Market Driver In Cyclosporine Drugs Market Industry 2025: Surge In Organ Transplantation Driving The Growth Market

The Business Research Company’s Cyclosporine Drugs Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, June 13, 2025 /⁨EINPresswire.com⁩/ -- There has been a significant expansion in the …

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia

Patients with myelofibrosis and anemia who received erythropoiesis-stimulating agents (ESAs) or danazol, both in combination with ruxolitinib (Jakafi), experienced similar spleen and symptom response rates vs the overall population, according to data from …

Global Chemotherapy-Induced Neutropenia Treatment Market To Reach $0.76 Billion By 2029 With A Growth Rate Of 5.3%

The Business Research Company's Chemotherapy-Induced Neutropenia Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, June 13, 2025 /⁨EINPresswire.com⁩/ -- According …

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile ...

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of …

Effective Dosage of Ciprofol for the Induction of General Anesthesia Across Diverse Age Groups in Adults: A Single-...

Introduction Propofol, a classic intravenous anesthetic, is associated with limitations such as injection pain and cardiorespiratory depression.1–4 Ciprofol, a novel GABAA receptor agonist developed in China, exhibits higher receptor affinity and reduced …

Aplastic Anemia Treatment Market Size In The 7MM Was ~USD 270 Million In 2023 And Is Further Expected To Increase By ...

(MENAFN- GetNews) DelveInsight's“ Aplastic Anemia Treatment Market Insights, Epidemiology, and Market Forecast – 2034 ” report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology, as well as the Aplastic Anemia …

Kalkine: Syntara Moves Closer to Breakthrough with Encouraging Myelofibrosis Trial Progress

Highlights Syntara receives fast track status for SNT-5505 Promising results continue in myelofibrosis Phase 2 trial Final results and pivotal study discussions expected in 2025 Clinical-stage biopharmaceutical company Syntara (ASX:SNT) has reported …

Clinical Validity of PLASMIC Score in aHUS Identification

Photo Credit: iStock.com/Rasi Bhadramani The following is a summary of “PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database,” published in the May 2025 issue of BMC Nephrology by …

JAK Inhibitor Selection Strategy: Risk-Guided Approach and Treatment Goals for Splenomegaly and Anemia

Optimizing Urology Care With Clinical Pharmacists

US Pharm. 2025;50(6):HS7-HS12. ABSTRACT: Clinical pharmacists are increasingly integral to urology care, contributing to medication optimization, infection control, and patient safety. Their interventions have improved outcomes in benign prostatic …

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple ...

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose …

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

Combining serplulimab (Hetronifly) with chemotherapy as frontline treatment conferred sustained overall survival (OS) and progression-free survival (PFS) benefits vs placebo plus chemotherapy among patients with extensive-stage small cell lung cancer (ES- …

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib (Sprycel) added to induction and consolidation therapy, followed by 12 months of maintenance, did not improve event-free survival (EFS) or overall survival (OS) compared with standard treatment for patients with core-binding factor acute myeloid …

How to spot developmental delays due to HDFN

Infants who have been diagnosed with hemolytic disease of the fetus and newborn (HDFN) may experience developmental delays due to the disease. Throughout the first 12 months of life, HDFN-affected babies will likely be monitored and screened by their …

Can prenatal vitamins help boost hair growth? A trichologist reveals the truth

Prenatal vitamins supplements for women who are pregnant or planning to conceive. They can support healthy fetal development. But should you use prenatal vitamins for hair growth? There are various nutrients that play a key role in supporting a healthy …

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

"[Tarlatamab] engages the immune system directly, instead of doing cytotoxic damage like traditional chemotherapies that kill the cancer directly. [We] are adding a mechanism of action that boosts or activates the immune system, which hopefully …

Linvoseltamab/Bortezomib Shows Consistent Safety in Relapsed/Refractory Multiple Myeloma

The combination of linvoseltamab, a BCMA x CD3 bispecific human monoclonal antibody, and bortezomib (Velcade) demonstrated a manageable safety profile in patients with relapsed/refractory multiple myeloma (RRMM), according to initial findings from the …

Mindworks NLP Offers a Smoking Cessation Group Hypnosis Live Event in Bellevue – June 21

Mindworks NLP announces a public group hypnosis seminar on June 21 to help participants quit smoking using powerful subconscious change techniques. BELLEVUE, WA, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- In a time when public health and …

Redefining Fabry Disease Care: Gene Therapy and Long-Acting ERT Prepare to Disrupt Status Quo | Competitive Intellignece

Fabry disease treatment is advancing rapidly with gene therapies and next-gen ERTs promising durable efficacy, reduced burden, and broader mutation coverage. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Fabry Disease, a rare, X …

Hunter Syndrome Therapeutics Evolve: Novel CNS-Targeting Therapies Set to Challenge Elaprase’s Market Monopoly

New CNS-penetrant therapies and gene therapies are poised to transform the Hunter Syndrome landscape, ending Elaprase’s long-standing treatment dominance. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Hunter Syndrome ( …

Rewriting the Playbook in MPS I: CNS-Penetrant ERTs and Gene Therapies Usher in a New Treatment Era | CI Insights

Emerging CNS‑targeting ERTs and gene therapies for MPS I show promise for neurocognitive benefits, reduced treatment burden, and better outcomes. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Mucopolysaccharidosis type I (MPS I) …

Thorncrest Dental Brings Advanced Laser Dentistry to Etobicoke with Picasso Soft Tissue Laser

ETOBICOKE, ONTARIO, CANADA, June 15, 2025 /⁨EINPresswire.com⁩/ -- Thorncrest Dental is proud to introduce the Picasso Soft Tissue Laser, a cutting-edge addition to its suite of dental technologies, now available to patients in the Etobicoke community. This …

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes ...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Tom Jackobs Offers Fractional Sales Management for Heart-Led Wellness Practices

New service helps mission-driven businesses improve sales performance without building a full in-house sales team. LOS ANGELES, CA, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Tom Jackobs, international sales strategist, is now offering …

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in ...

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …

New national report reveals critical gaps in asthma and COPD care

A new NRAP report has highlighted persistent and widespread gaps in the care of people with asthma and chronic obstructive pulmonary disease (COPD) across England and Wales, calling on integrated care boards and local health boards to mandate all eligible …

RCP statement on Air India crash

RCP president, Dr Mumtaz Patel, said: ‘We are devastated by the plane crash in India today and the many lives it has claimed. Our thoughts and prayers are with everyone affected by this tragic incident. ‘We are directly contacting all our RCP members in …

Latest ‘Focus on physicians’ survey closes with over 2000 responses from doctors across the UK

The 2025 ‘Focus on physicians’ survey – a joint project between the Royal College of Physicians (RCP), the Royal College of Physicians and Surgeons of Glasgow (RCPSG) and the Royal College of Physicians of Edinburgh (RCPE) – has now closed. The ‘Focus on …

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ...

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of …

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle- …

Blue Sky Scrubs Celebrates World Wind Day: Championing Clean Energy for a Healthier Planet

Blue Sky Medical Scrubs and Scrub Caps Celebrates World Wind Day: Championing Clean Energy for a Healthier Planet AUSTIN, TX, UNITED STATES, June 14, 2025 /⁨EINPresswire.com⁩/ -- In celebration of World Wind Day, Blue Sky Scrubs proudly joins the …

Cherry Blossoms and The Other Side, A Poetic Journey Through Grief and Beyond

LAWRENCE, MA, UNITED STATES, June 14, 2025 /⁨EINPresswire.com⁩/ -- Acclaimed writer and visual dramatist Dennis Mullings presents a powerful double release with Cherry Blossoms and The Other Side, two moving and visually arresting plays that navigate the …

ICN elects new President, José Luis Cobos Serrano and a new Board of Directors

ICN announces Dr José Luis Cobos Serrano as its 30th President at its Congress in Helsinki HELSINKI, FINLAND, June 14, 2025 /⁨EINPresswire.com⁩/ -- At the closing ceremony of ICN Congress 2025, ICN announced that it has elected Dr José Luis Cobos …

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in ...

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex …

ThinkCareBelieve: Week 21 of America's Progress under President Trump

Washington D.C., June 14, 2025 (GLOBE NEWSWIRE) -- You can find the article here:  https://thinkcarebelieve.blog/2025/06/14/week-21-of-americas-progress-under-president-trump/ ThinkCareBelieve has published an article on the …